BLLN Stock Analysis: Buy, Sell, or Hold?
$102.98
2.25 (2.24%)
▲
5d:
-0.94%
30d:
+19.53%
90d:
+29.38%
HOLD
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When BLLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BLLN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: BLLN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$43.55
Based on 11.2% avg growth
INTRINSIC VALUE TODAY
$27.04
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BLLN is currently trading at $102.97, which is considered extended relative to its 30-day fair value range of $87.75 to $102.56. From a valuation perspective, the stock is trading at a discount (Forward PE: 97.8) compared to its historical average (126.2). Remarkably, the market is currently pricing in an annual earnings decline of 8.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BLLN is in a uptrend. Immediate support is located at $94.20, while resistance sits at $106.55.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $117.71 (+16.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BLLN is in a uptrend. Immediate support is located at $94.20, while resistance sits at $106.55.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $117.71 (+16.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$87.75 -
$102.56
Company Quality Score
57/100
(HOLD)
Options IV Signal
3th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
58.5%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 3th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($117.71)
Trading Range Analysis
30-Day Trading Range
$87.75 -
$102.56
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$9.65
(9.4%)
Support & Resistance Levels
Support Level
$94.20
Resistance Level
$106.55
Current Trend
Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
97.79
Wall Street Target
$117.71
(+16.9%)
Revenue Growth (YoY)
83.8%
Profit Margin
7.0%
Valuation Discount vs History
-8.2% cheaper
PE vs Historical
97.8 vs 126.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.2%
(market-implied from PE analysis)
1-Year Target
$92.46
(-8%)
2-Year Target
$84.88
(-16%)
3-Year Target
$77.92
(-23%)
3-Yr Target (if PE normalizes)
(PE: 98→126)
$100.56
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 97.8, Growth: 18.4%)
$167.14
(+66%)
Base:
(SPY PE: 21.8, Growth: 18.4%)
$37.23
(-63%)
Bear:
(PE: 18.5, Growth: 18.4%)
$31.64
(-69%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (191x PE), but valuation improves significantly next year (98x PE) as earnings recover.
Trailing PE: 191.18 | Current EPS (TTM): $0.55
Bull Case
$216.61
(+115%)
Analyst growth 87.3%, PE expands to 210.3
Base Case
$196.92
(+96%)
Market implied 87.3%, PE stable at 191.2
Bear Case
$71.50
(-29%)
Severe decline -20.0%, PE contracts to 162.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 97.8 to 126.2
Stabilization Target:
$129.99
(+29.1%)
PE Expansion Potential:
+29.1%
Share & Embed Analysis
Last updated: June 23, 2026 11:47 AM ET
Data refreshes hourly during market hours. Next update: 12:47 PM
Data refreshes hourly during market hours. Next update: 12:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BLLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$599 | 55 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$142 | 56 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$242 | 51 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$260 | 62 BUY |